bluuebunny/crossref_metadata_2025 huggingface dataset:
Supplementary Table S1 from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study
Authors: Koyama Takafumi , Shimizu Toshio , Kojima Yuki , Sudo Kazuki , Okuma Hitomi Sumiyoshi. , Shimoi Tatsunori , Ichikawa Hitoshi , Kohsaka Shinji , Sadachi Ryo , Hirakawa Akihiro , Yoshida Akihiko , Ando Reiko Makihara. , Ueno Toshihide , Yanagaki Mitsuru , Matsui Naoko , Nakamura Kenichi , Yamamoto Noboru , Yonemori Kan
Published: September 2024

Representativeness of study participant
Supplementary Figure S4B from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study
Authors: Koyama Takafumi , Shimizu Toshio , Kojima Yuki , Sudo Kazuki , Okuma Hitomi Sumiyoshi. , Shimoi Tatsunori , Ichikawa Hitoshi , Kohsaka Shinji , Sadachi Ryo , Hirakawa Akihiro , Yoshida Akihiko , Ando Reiko Makihara. , Ueno Toshihide , Yanagaki Mitsuru , Matsui Naoko , Nakamura Kenichi , Yamamoto Noboru , Yonemori Kan
Published: September 2024

Anti-tumor activity
Supplementary Figure S3 from Clinical activity and exploratory resistance mechanism of milademetan, an MDM2 inhibitor, in intimal sarcoma with MDM2 amplification: an open-label phase 1b/2 study
Authors: Koyama Takafumi , Shimizu Toshio , Kojima Yuki , Sudo Kazuki , Okuma Hitomi Sumiyoshi. , Shimoi Tatsunori , Ichikawa Hitoshi , Kohsaka Shinji , Sadachi Ryo , Hirakawa Akihiro , Yoshida Akihiko , Ando Reiko Makihara. , Ueno Toshihide , Yanagaki Mitsuru , Matsui Naoko , Nakamura Kenichi , Yamamoto Noboru , Yonemori Kan
Published: September 2024

Supplementary Dosing schedule in 11 patients
Supplementary Table 3 from Resistance to selective FGFR inhibitors in FGFR-driven urothelial cancer
Authors: Facchinetti Francesco , Hollebecque Antoine , Braye Floriane , Vasseur Damien , Pradat Yoann , Bahleda Rastislav , Pobel Cedric , Bigot Ludovic , Deas Olivier , Florez Arango Juan David , Guaitoli Giorgia , Mizuta Hayato , Combarel David , Tselikas Lambros , Michiels Stefan , Nikolaev Sergey I. , Scoazec Jean-Yves , Ponce-Aix Santiago , Besse Benjamin , Olaussen Ken A. , Loriot Yohann , Friboulet Luc
Published: September 2024

IC50 values of Ba/F3 cells harboring FGFR3:TACC3 mutants exposed to eight selective FGFR inhibitors.
Supplementary Table 2 from Resistance to selective FGFR inhibitors in FGFR-driven urothelial cancer
Authors: Facchinetti Francesco , Hollebecque Antoine , Braye Floriane , Vasseur Damien , Pradat Yoann , Bahleda Rastislav , Pobel Cedric , Bigot Ludovic , Deas Olivier , Florez Arango Juan David , Guaitoli Giorgia , Mizuta Hayato , Combarel David , Tselikas Lambros , Michiels Stefan , Nikolaev Sergey I. , Scoazec Jean-Yves , Ponce-Aix Santiago , Besse Benjamin , Olaussen Ken A. , Loriot Yohann , Friboulet Luc
Published: September 2024

Systemic treatment received by patients prior to selective FGFR inhibitors, according to the detection of FGFR kinase domain mutations and/or PI3K/mTOR pathway alterations.
Supplementary Table 1 from Resistance to selective FGFR inhibitors in FGFR-driven urothelial cancer
Authors: Facchinetti Francesco , Hollebecque Antoine , Braye Floriane , Vasseur Damien , Pradat Yoann , Bahleda Rastislav , Pobel Cedric , Bigot Ludovic , Deas Olivier , Florez Arango Juan David , Guaitoli Giorgia , Mizuta Hayato , Combarel David , Tselikas Lambros , Michiels Stefan , Nikolaev Sergey I. , Scoazec Jean-Yves , Ponce-Aix Santiago , Besse Benjamin , Olaussen Ken A. , Loriot Yohann , Friboulet Luc
Published: September 2024

Patient population, treatment outcomes and post-progression sample availability.
Supplementary Figure 2 from Resistance to selective FGFR inhibitors in FGFR-driven urothelial cancer
Authors: Facchinetti Francesco , Hollebecque Antoine , Braye Floriane , Vasseur Damien , Pradat Yoann , Bahleda Rastislav , Pobel Cedric , Bigot Ludovic , Deas Olivier , Florez Arango Juan David , Guaitoli Giorgia , Mizuta Hayato , Combarel David , Tselikas Lambros , Michiels Stefan , Nikolaev Sergey I. , Scoazec Jean-Yves , Ponce-Aix Santiago , Besse Benjamin , Olaussen Ken A. , Loriot Yohann , Friboulet Luc
Published: September 2024

Documentation of the allelic status in cis of FGFR3 S249C and V553L mutations from MR406 tissue biopsy.
Supplementary Table S6 from An inflammatory checkpoint generated by IL1RN splicing offers therapeutic opportunity for KRAS mutant intrahepatic cholangiocarcinoma
Authors: Zhang Mao , Huang Yingying , Pan Jiaomeng , Sang Chen , Lin Youpei , Dong Liangqing , Shen Xia , Wu Yingcheng , Song Guohe , Ji Shuyi , Liu Fen , Wang Mengcheng , Zheng Yuyan , Zhang Sirui , Wang Zefeng , Ren Jianke , Gao Daming , Zhou Jian , Fan Jia , Wei Wu , Lin Jian , Gao Qiang
Published: September 2024

Supplementary Table S6. GO term and KEGG pathway information in Gzmb+ Cd8+ T cells.
Supplementary Table S4 from An inflammatory checkpoint generated by IL1RN splicing offers therapeutic opportunity for KRAS mutant intrahepatic cholangiocarcinoma
Authors: Zhang Mao , Huang Yingying , Pan Jiaomeng , Sang Chen , Lin Youpei , Dong Liangqing , Shen Xia , Wu Yingcheng , Song Guohe , Ji Shuyi , Liu Fen , Wang Mengcheng , Zheng Yuyan , Zhang Sirui , Wang Zefeng , Ren Jianke , Gao Daming , Zhou Jian , Fan Jia , Wei Wu , Lin Jian , Gao Qiang
Published: September 2024

Supplementary Table S4. Neutrophil-related information.
Supplementary Table S3 from An inflammatory checkpoint generated by IL1RN splicing offers therapeutic opportunity for KRAS mutant intrahepatic cholangiocarcinoma
Authors: Zhang Mao , Huang Yingying , Pan Jiaomeng , Sang Chen , Lin Youpei , Dong Liangqing , Shen Xia , Wu Yingcheng , Song Guohe , Ji Shuyi , Liu Fen , Wang Mengcheng , Zheng Yuyan , Zhang Sirui , Wang Zefeng , Ren Jianke , Gao Daming , Zhou Jian , Fan Jia , Wei Wu , Lin Jian , Gao Qiang
Published: September 2024

Supplementary Table S3. Signature and marker information.
Supplementary Tables 1-12 from Colorectal cancer organoid-stroma biobank allows subtype-specific assessment of individualized therapy responses
Authors: Farin Henner F. , Mosa Mohammed H. , Ndreshkjana Benardina , Grebbin Britta M. , Ritter Birgit , Menche Constantin , Kennel Kilian B. , Ziegler Paul K. , Szabo Lili , Bollrath Julia , Rieder Dietmar , Michels Birgitta E. , Kress Alena , Bozlar Muge , Darvishi Tahmineh , Stier Sara , Kur Ivan-Maximiliano , Bankov Katrin , Kesselring Rebecca , Fichtner-Feigl Stefan , Brune Bernhard , Goetze Thorsten O. , Al-Batran Salah-Eddin , Brandts Christian H. , Bechstein Wolf O. , Wild Peter J. , Weigert Andreas , Muller Susanne , Knapp Stefan , Trajanoski Zlatko , Greten Florian R.
Published: September 2024

Supplementary Table S1 shows the clinical data of the CRC organoid-stroma cohort.

Supplementary Table S2 shows the inventory of available materials and molecular analyses.

Supplementary Table S3 shows the selected variant types for whole exome analysis.

Supplementary Table S4 summarizes the genetic characterization of CRC models.

Supplementary Table S5 shows the classification according to the consensus molecular subtypes (CMS).

Supplementary Table S6 shows classification according to the CRC intrinsic subtypes (CRIS).

Supplementary Table S7 summarizes the functional data in mono- and co-cultures.

Supplementary Table S8 shows drug sensitivity of CRC organoids in co-culture with autologous and heterologous fibroblasts.

Supplementary Table S9 show the drug sensitivity in all biobank models in mono- and co-culture.

Supplementary Table S10 shows the cell viability data of the chemogenomic library screens in resistant co-culture models.

Supplementary Table S11 shows the identified drug sensitivity and resistance signatures.

Supplementary Table S12 lists all antibodies and primer sequences used in this study.
Table S6 from Inhibition of METTL3 results in a cell-intrinsic interferon response that enhances
anti-tumour immunity
Authors: Guirguis Andrew A. , Ofir-Rosenfeld Yaara , Knezevic Kathy , Blackaby Wesley , Hardick David , Chan Yih-Chih , Motazedian Ali , Gillespie Andrea , Vassiliadis Dane , Lam Enid YN. , Tran Kevin , Andrews Byron , Harbour Michael E. , Vasiliauskaite Lina , Saunders Claire J. , Tsagkogeorga Georgia , Azevedo Aleksandra , Obacz Joanna , Pilka Ewa S. , Carkill Marie , MacPherson Laura , Wainwright Elanor N. , Liddicoat Brian , Blyth Benjamin J. , Albertella Mark R. , Rausch Oliver , Dawson Mark A.
Published: September 2024

LMOs for sc-RNA sequencing
Table S3 from Inhibition of METTL3 results in a cell-intrinsic interferon response that enhances
anti-tumour immunity
Authors: Guirguis Andrew A. , Ofir-Rosenfeld Yaara , Knezevic Kathy , Blackaby Wesley , Hardick David , Chan Yih-Chih , Motazedian Ali , Gillespie Andrea , Vassiliadis Dane , Lam Enid YN. , Tran Kevin , Andrews Byron , Harbour Michael E. , Vasiliauskaite Lina , Saunders Claire J. , Tsagkogeorga Georgia , Azevedo Aleksandra , Obacz Joanna , Pilka Ewa S. , Carkill Marie , MacPherson Laura , Wainwright Elanor N. , Liddicoat Brian , Blyth Benjamin J. , Albertella Mark R. , Rausch Oliver , Dawson Mark A.
Published: September 2024

WB + other antibodies
Table S2 from Inhibition of METTL3 results in a cell-intrinsic interferon response that enhances
anti-tumour immunity
Authors: Guirguis Andrew A. , Ofir-Rosenfeld Yaara , Knezevic Kathy , Blackaby Wesley , Hardick David , Chan Yih-Chih , Motazedian Ali , Gillespie Andrea , Vassiliadis Dane , Lam Enid YN. , Tran Kevin , Andrews Byron , Harbour Michael E. , Vasiliauskaite Lina , Saunders Claire J. , Tsagkogeorga Georgia , Azevedo Aleksandra , Obacz Joanna , Pilka Ewa S. , Carkill Marie , MacPherson Laura , Wainwright Elanor N. , Liddicoat Brian , Blyth Benjamin J. , Albertella Mark R. , Rausch Oliver , Dawson Mark A.
Published: September 2024

Flow antibodies
Figure S5 from Inhibition of METTL3 results in a cell-intrinsic interferon response that enhances
anti-tumour immunity
Authors: Guirguis Andrew A. , Ofir-Rosenfeld Yaara , Knezevic Kathy , Blackaby Wesley , Hardick David , Chan Yih-Chih , Motazedian Ali , Gillespie Andrea , Vassiliadis Dane , Lam Enid YN. , Tran Kevin , Andrews Byron , Harbour Michael E. , Vasiliauskaite Lina , Saunders Claire J. , Tsagkogeorga Georgia , Azevedo Aleksandra , Obacz Joanna , Pilka Ewa S. , Carkill Marie , MacPherson Laura , Wainwright Elanor N. , Liddicoat Brian , Blyth Benjamin J. , Albertella Mark R. , Rausch Oliver , Dawson Mark A.
Published: September 2024

Co-culture assays + human PBMC data
Figure S4 from Inhibition of METTL3 results in a cell-intrinsic interferon response that enhances
anti-tumour immunity
Authors: Guirguis Andrew A. , Ofir-Rosenfeld Yaara , Knezevic Kathy , Blackaby Wesley , Hardick David , Chan Yih-Chih , Motazedian Ali , Gillespie Andrea , Vassiliadis Dane , Lam Enid YN. , Tran Kevin , Andrews Byron , Harbour Michael E. , Vasiliauskaite Lina , Saunders Claire J. , Tsagkogeorga Georgia , Azevedo Aleksandra , Obacz Joanna , Pilka Ewa S. , Carkill Marie , MacPherson Laura , Wainwright Elanor N. , Liddicoat Brian , Blyth Benjamin J. , Albertella Mark R. , Rausch Oliver , Dawson Mark A.
Published: September 2024

Nanopore workflow
Figure S2 from Inhibition of METTL3 results in a cell-intrinsic interferon response that enhances
anti-tumour immunity
Authors: Guirguis Andrew A. , Ofir-Rosenfeld Yaara , Knezevic Kathy , Blackaby Wesley , Hardick David , Chan Yih-Chih , Motazedian Ali , Gillespie Andrea , Vassiliadis Dane , Lam Enid YN. , Tran Kevin , Andrews Byron , Harbour Michael E. , Vasiliauskaite Lina , Saunders Claire J. , Tsagkogeorga Georgia , Azevedo Aleksandra , Obacz Joanna , Pilka Ewa S. , Carkill Marie , MacPherson Laura , Wainwright Elanor N. , Liddicoat Brian , Blyth Benjamin J. , Albertella Mark R. , Rausch Oliver , Dawson Mark A.
Published: September 2024

Gene expression changes + pathways
Supplementary Video 1 from GABA regulates electrical activity and tumor initiation in melanoma
Authors: Tagore Mohita , Hergenreder Emiliano , Perlee Sarah C. , Cruz Nelly M. , Menocal Laura , Suresh Shruthy , Chan Eric , Baron Maayan , Melendez Stephanie , Dave Asim , Chatila Walid K. , Nsengimana Jeremie , Koche Richard P. , Hollmann Travis J. , Ideker Trey , Studer Lorenz , Schietinger Andrea , White Richard M.
Published: September 2024

3D rendering of melanoma/keratinocyte contacts in zebrafish embryos
Figure S3 from Dual immune checkpoint blockade induces analogous alterations in the dysfunctional CD8+ T cell and activated Treg compartment
Authors: van der Leun Anne M. , Traets Joleen J.H. , Vos Joris L. , Elbers Joris B.W. , Patiwael Sanne , Qiao Xiaohang , Machuca-Ostos Mercedes , Thommen Daniela S. , Haanen John B.A.G. , Schumacher Ton N.M. , Zuur Charlotte L.
Published: September 2024

Validation of the differential abundance of Treg subpopulations at baseline using orthogonal strategies and an independent HNSCC dataset.
Figure S1 from Dual immune checkpoint blockade induces analogous alterations in the dysfunctional CD8+ T cell and activated Treg compartment
Authors: van der Leun Anne M. , Traets Joleen J.H. , Vos Joris L. , Elbers Joris B.W. , Patiwael Sanne , Qiao Xiaohang , Machuca-Ostos Mercedes , Thommen Daniela S. , Haanen John B.A.G. , Schumacher Ton N.M. , Zuur Charlotte L.
Published: September 2024

Cell state annotations of CD45+ cells and clonality of T cells isolated from HNSCC biopsies.
Supplementary Table S3 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
Authors: Engstrom Lars D. , Aranda Ruth , Waters Laura , Moya Krystal , Bowcut Vickie , Vegar Laura , Trinh David , Hebbert Allan , Smith Christopher R. , Kulyk Svitlana , Lawson J David. , He Leo , Hover Laura D. , Fernandez-Banet Julio , Hallin Jill , Vanderpool Darin , Briere David M. , Blaj Alice , Marx Matthew A. , Rodon Jordi , Offin Michael , Arbour Kathryn C. , Johnson Melissa L. , Kwiatkowski David J. , Janne Pasi A. , Haddox Candace L. , Papadopoulos Kyriakos P. , Henry Jason T. , Leventakos Konstantinos , Christensen James G. , Shazer Ronald , Olson Peter
Published: September 2024

5-Day in vitro viability data
Supplementary Table S2 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
Authors: Engstrom Lars D. , Aranda Ruth , Waters Laura , Moya Krystal , Bowcut Vickie , Vegar Laura , Trinh David , Hebbert Allan , Smith Christopher R. , Kulyk Svitlana , Lawson J David. , He Leo , Hover Laura D. , Fernandez-Banet Julio , Hallin Jill , Vanderpool Darin , Briere David M. , Blaj Alice , Marx Matthew A. , Rodon Jordi , Offin Michael , Arbour Kathryn C. , Johnson Melissa L. , Kwiatkowski David J. , Janne Pasi A. , Haddox Candace L. , Papadopoulos Kyriakos P. , Henry Jason T. , Leventakos Konstantinos , Christensen James G. , Shazer Ronald , Olson Peter
Published: September 2024

PTMScan data tables
Supplementary Materials and Methods from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
Authors: Engstrom Lars D. , Aranda Ruth , Waters Laura , Moya Krystal , Bowcut Vickie , Vegar Laura , Trinh David , Hebbert Allan , Smith Christopher R. , Kulyk Svitlana , Lawson J David. , He Leo , Hover Laura D. , Fernandez-Banet Julio , Hallin Jill , Vanderpool Darin , Briere David M. , Blaj Alice , Marx Matthew A. , Rodon Jordi , Offin Michael , Arbour Kathryn C. , Johnson Melissa L. , Kwiatkowski David J. , Janne Pasi A. , Haddox Candace L. , Papadopoulos Kyriakos P. , Henry Jason T. , Leventakos Konstantinos , Christensen James G. , Shazer Ronald , Olson Peter
Published: September 2024

Materials and methods related to supplemental data
Supplementary Figure S7 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
Authors: Engstrom Lars D. , Aranda Ruth , Waters Laura , Moya Krystal , Bowcut Vickie , Vegar Laura , Trinh David , Hebbert Allan , Smith Christopher R. , Kulyk Svitlana , Lawson J David. , He Leo , Hover Laura D. , Fernandez-Banet Julio , Hallin Jill , Vanderpool Darin , Briere David M. , Blaj Alice , Marx Matthew A. , Rodon Jordi , Offin Michael , Arbour Kathryn C. , Johnson Melissa L. , Kwiatkowski David J. , Janne Pasi A. , Haddox Candace L. , Papadopoulos Kyriakos P. , Henry Jason T. , Leventakos Konstantinos , Christensen James G. , Shazer Ronald , Olson Peter
Published: September 2024

Supplemental pharmacodynamic effects of MRTX1719 in patients
Supplementary Figure S6 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
Authors: Engstrom Lars D. , Aranda Ruth , Waters Laura , Moya Krystal , Bowcut Vickie , Vegar Laura , Trinh David , Hebbert Allan , Smith Christopher R. , Kulyk Svitlana , Lawson J David. , He Leo , Hover Laura D. , Fernandez-Banet Julio , Hallin Jill , Vanderpool Darin , Briere David M. , Blaj Alice , Marx Matthew A. , Rodon Jordi , Offin Michael , Arbour Kathryn C. , Johnson Melissa L. , Kwiatkowski David J. , Janne Pasi A. , Haddox Candace L. , Papadopoulos Kyriakos P. , Henry Jason T. , Leventakos Konstantinos , Christensen James G. , Shazer Ronald , Olson Peter
Published: September 2024

Supplemental in vitro and in vivo efficacy of MRTX1719
Supplementary Figure S5 from MRTX1719 is an MTA-cooperative PRMT5 inhibitor that exhibits synthetic lethality in preclinical models and patients with MTAP deleted cancer
Authors: Engstrom Lars D. , Aranda Ruth , Waters Laura , Moya Krystal , Bowcut Vickie , Vegar Laura , Trinh David , Hebbert Allan , Smith Christopher R. , Kulyk Svitlana , Lawson J David. , He Leo , Hover Laura D. , Fernandez-Banet Julio , Hallin Jill , Vanderpool Darin , Briere David M. , Blaj Alice , Marx Matthew A. , Rodon Jordi , Offin Michael , Arbour Kathryn C. , Johnson Melissa L. , Kwiatkowski David J. , Janne Pasi A. , Haddox Candace L. , Papadopoulos Kyriakos P. , Henry Jason T. , Leventakos Konstantinos , Christensen James G. , Shazer Ronald , Olson Peter
Published: September 2024

Co-culture experiments with MTAP-expressing fibroblasts
Figure S7 from The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer
Authors: Mattox Austin K. , Douville Christopher , Wang Yuxuan , Popoli Maria , Ptak Janine , Silliman Natalie , Dobbyn Lisa , Schaefer Joy , Lu Steve , Pearlman Alexander H. , Cohen Joshua D. , Tie Jeanne , Gibbs Peter , Lahouel Kamel , Bettegowda Chetan , Hruban Ralph H. , Tomasetti Cristian , Jiang Peiyong , Chan K.C. Allen , Lo Yuk Ming Dennis , Papadopoulos Nickolas , Kinzler Kenneth W. , Vogelstein Bert
Published: September 2024

Supplemental Figure 7. The amount of total cfDNA before and after surgery in patients with pancreatic cancer.
Figure S4 from The origin of highly elevated cell-free DNA in healthy individuals and patients with pancreatic, colorectal, lung, or ovarian cancer
Authors: Mattox Austin K. , Douville Christopher , Wang Yuxuan , Popoli Maria , Ptak Janine , Silliman Natalie , Dobbyn Lisa , Schaefer Joy , Lu Steve , Pearlman Alexander H. , Cohen Joshua D. , Tie Jeanne , Gibbs Peter , Lahouel Kamel , Bettegowda Chetan , Hruban Ralph H. , Tomasetti Cristian , Jiang Peiyong , Chan K.C. Allen , Lo Yuk Ming Dennis , Papadopoulos Nickolas , Kinzler Kenneth W. , Vogelstein Bert
Published: September 2024

Supplemental Figure 4. Methylation profiles using quadratic programming vs. non-negative least- squares regression using the reference matrix described in Sun et al. (3). Pearson’s correlation coefficient and p values are presented at the bottom of this figure, showing the derived contributions from each of the 12 tissue types that could be assessed.
Table S9 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways
Authors: Venneti Sriram , Kawakibi Abed Rahman , Ji Sunjong , Waszak Sebastian M. , Sweha Stefan R. , Mota Mateus , Pun Matthew , Deogharkar Akash , Chung Chan , Tarapore Rohinton S. , Ramage Samuel , Chi Andrew , Wen Patrick Y. , Arrillaga-Romany Isabel , Batchelor Tracy T. , Butowski Nicholas A. , Sumrall Ashley , Shonka Nicole , Harrison Rebecca A. , de Groot John , Mehta Minesh , Hall Matthew D. , Daghistani Doured , Cloughesy Timothy F. , Ellingson Benjamin M. , Beccaria Kevin , Varlet Pascale , Kim Michelle M. , Umemura Yoshie , Garton Hugh , Franson Andrea , Schwartz Jonathan , Jain Rajan , Kachman Maureen , Baum Heidi , Burant Charles F. , Mottl Sophie L. , Cartaxo Rodrigo T. , John Vishal , Messinger Dana , Qin Tingting , Peterson Erik , Sajjakulnukit Peter , Ravi Karthik , Waugh Alyssa , Walling Dustin , Ding Yujie , Xia Ziyun , Schwendeman Anna , Hawes Debra , Yang Fusheng , Judkins Alexander R. , Wahl Daniel , Lyssiotis Costas A. , de la Nava Daniel , Alonso Marta M. , Eze Augustine , Spitzer Jasper , Schmidt Susanne V. , Duchatel Ryan J. , Dun Matthew D. , Cain Jason E. , Jiang Li , Stopka Sylwia A. , Baquer Gerard , Regan Michael S. , Filbin Mariella G. , Agar Nathalie Y.R. , Zhao Lili , Kumar-Sinha Chandan , Mody Rajen , Chinnaiyan Arul , Kurokawa Ryo , Pratt Drew , Yadav Viveka N. , Grill Jacques , Kline Cassie , Mueller Sabine , Resnick Adam , Nazarian Javad , Allen Joshua E. , Odia Yazmin , Gardner Sharon L. , Koschmann Carl
Published: September 2024

Upregulated and downregulated genes in DIPG007 cells treated with ONC201 versus vehicle.
Table S8 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways
Authors: Venneti Sriram , Kawakibi Abed Rahman , Ji Sunjong , Waszak Sebastian M. , Sweha Stefan R. , Mota Mateus , Pun Matthew , Deogharkar Akash , Chung Chan , Tarapore Rohinton S. , Ramage Samuel , Chi Andrew , Wen Patrick Y. , Arrillaga-Romany Isabel , Batchelor Tracy T. , Butowski Nicholas A. , Sumrall Ashley , Shonka Nicole , Harrison Rebecca A. , de Groot John , Mehta Minesh , Hall Matthew D. , Daghistani Doured , Cloughesy Timothy F. , Ellingson Benjamin M. , Beccaria Kevin , Varlet Pascale , Kim Michelle M. , Umemura Yoshie , Garton Hugh , Franson Andrea , Schwartz Jonathan , Jain Rajan , Kachman Maureen , Baum Heidi , Burant Charles F. , Mottl Sophie L. , Cartaxo Rodrigo T. , John Vishal , Messinger Dana , Qin Tingting , Peterson Erik , Sajjakulnukit Peter , Ravi Karthik , Waugh Alyssa , Walling Dustin , Ding Yujie , Xia Ziyun , Schwendeman Anna , Hawes Debra , Yang Fusheng , Judkins Alexander R. , Wahl Daniel , Lyssiotis Costas A. , de la Nava Daniel , Alonso Marta M. , Eze Augustine , Spitzer Jasper , Schmidt Susanne V. , Duchatel Ryan J. , Dun Matthew D. , Cain Jason E. , Jiang Li , Stopka Sylwia A. , Baquer Gerard , Regan Michael S. , Filbin Mariella G. , Agar Nathalie Y.R. , Zhao Lili , Kumar-Sinha Chandan , Mody Rajen , Chinnaiyan Arul , Kurokawa Ryo , Pratt Drew , Yadav Viveka N. , Grill Jacques , Kline Cassie , Mueller Sabine , Resnick Adam , Nazarian Javad , Allen Joshua E. , Odia Yazmin , Gardner Sharon L. , Koschmann Carl
Published: September 2024

Expression values, Spearman’s correlation coefficient, and GSEA of genes associated with positive or negative correlation with radiographic response to ONC201 treatment.
Table S3 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways
Authors: Venneti Sriram , Kawakibi Abed Rahman , Ji Sunjong , Waszak Sebastian M. , Sweha Stefan R. , Mota Mateus , Pun Matthew , Deogharkar Akash , Chung Chan , Tarapore Rohinton S. , Ramage Samuel , Chi Andrew , Wen Patrick Y. , Arrillaga-Romany Isabel , Batchelor Tracy T. , Butowski Nicholas A. , Sumrall Ashley , Shonka Nicole , Harrison Rebecca A. , de Groot John , Mehta Minesh , Hall Matthew D. , Daghistani Doured , Cloughesy Timothy F. , Ellingson Benjamin M. , Beccaria Kevin , Varlet Pascale , Kim Michelle M. , Umemura Yoshie , Garton Hugh , Franson Andrea , Schwartz Jonathan , Jain Rajan , Kachman Maureen , Baum Heidi , Burant Charles F. , Mottl Sophie L. , Cartaxo Rodrigo T. , John Vishal , Messinger Dana , Qin Tingting , Peterson Erik , Sajjakulnukit Peter , Ravi Karthik , Waugh Alyssa , Walling Dustin , Ding Yujie , Xia Ziyun , Schwendeman Anna , Hawes Debra , Yang Fusheng , Judkins Alexander R. , Wahl Daniel , Lyssiotis Costas A. , de la Nava Daniel , Alonso Marta M. , Eze Augustine , Spitzer Jasper , Schmidt Susanne V. , Duchatel Ryan J. , Dun Matthew D. , Cain Jason E. , Jiang Li , Stopka Sylwia A. , Baquer Gerard , Regan Michael S. , Filbin Mariella G. , Agar Nathalie Y.R. , Zhao Lili , Kumar-Sinha Chandan , Mody Rajen , Chinnaiyan Arul , Kurokawa Ryo , Pratt Drew , Yadav Viveka N. , Grill Jacques , Kline Cassie , Mueller Sabine , Resnick Adam , Nazarian Javad , Allen Joshua E. , Odia Yazmin , Gardner Sharon L. , Koschmann Carl
Published: September 2024

Individual cases from historical control datasets.
Table S2 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways
Authors: Venneti Sriram , Kawakibi Abed Rahman , Ji Sunjong , Waszak Sebastian M. , Sweha Stefan R. , Mota Mateus , Pun Matthew , Deogharkar Akash , Chung Chan , Tarapore Rohinton S. , Ramage Samuel , Chi Andrew , Wen Patrick Y. , Arrillaga-Romany Isabel , Batchelor Tracy T. , Butowski Nicholas A. , Sumrall Ashley , Shonka Nicole , Harrison Rebecca A. , de Groot John , Mehta Minesh , Hall Matthew D. , Daghistani Doured , Cloughesy Timothy F. , Ellingson Benjamin M. , Beccaria Kevin , Varlet Pascale , Kim Michelle M. , Umemura Yoshie , Garton Hugh , Franson Andrea , Schwartz Jonathan , Jain Rajan , Kachman Maureen , Baum Heidi , Burant Charles F. , Mottl Sophie L. , Cartaxo Rodrigo T. , John Vishal , Messinger Dana , Qin Tingting , Peterson Erik , Sajjakulnukit Peter , Ravi Karthik , Waugh Alyssa , Walling Dustin , Ding Yujie , Xia Ziyun , Schwendeman Anna , Hawes Debra , Yang Fusheng , Judkins Alexander R. , Wahl Daniel , Lyssiotis Costas A. , de la Nava Daniel , Alonso Marta M. , Eze Augustine , Spitzer Jasper , Schmidt Susanne V. , Duchatel Ryan J. , Dun Matthew D. , Cain Jason E. , Jiang Li , Stopka Sylwia A. , Baquer Gerard , Regan Michael S. , Filbin Mariella G. , Agar Nathalie Y.R. , Zhao Lili , Kumar-Sinha Chandan , Mody Rajen , Chinnaiyan Arul , Kurokawa Ryo , Pratt Drew , Yadav Viveka N. , Grill Jacques , Kline Cassie , Mueller Sabine , Resnick Adam , Nazarian Javad , Allen Joshua E. , Odia Yazmin , Gardner Sharon L. , Koschmann Carl
Published: September 2024

Individual patients with H3K27M-mutant DMG treated with ONC201.
Table S14 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways
Authors: Venneti Sriram , Kawakibi Abed Rahman , Ji Sunjong , Waszak Sebastian M. , Sweha Stefan R. , Mota Mateus , Pun Matthew , Deogharkar Akash , Chung Chan , Tarapore Rohinton S. , Ramage Samuel , Chi Andrew , Wen Patrick Y. , Arrillaga-Romany Isabel , Batchelor Tracy T. , Butowski Nicholas A. , Sumrall Ashley , Shonka Nicole , Harrison Rebecca A. , de Groot John , Mehta Minesh , Hall Matthew D. , Daghistani Doured , Cloughesy Timothy F. , Ellingson Benjamin M. , Beccaria Kevin , Varlet Pascale , Kim Michelle M. , Umemura Yoshie , Garton Hugh , Franson Andrea , Schwartz Jonathan , Jain Rajan , Kachman Maureen , Baum Heidi , Burant Charles F. , Mottl Sophie L. , Cartaxo Rodrigo T. , John Vishal , Messinger Dana , Qin Tingting , Peterson Erik , Sajjakulnukit Peter , Ravi Karthik , Waugh Alyssa , Walling Dustin , Ding Yujie , Xia Ziyun , Schwendeman Anna , Hawes Debra , Yang Fusheng , Judkins Alexander R. , Wahl Daniel , Lyssiotis Costas A. , de la Nava Daniel , Alonso Marta M. , Eze Augustine , Spitzer Jasper , Schmidt Susanne V. , Duchatel Ryan J. , Dun Matthew D. , Cain Jason E. , Jiang Li , Stopka Sylwia A. , Baquer Gerard , Regan Michael S. , Filbin Mariella G. , Agar Nathalie Y.R. , Zhao Lili , Kumar-Sinha Chandan , Mody Rajen , Chinnaiyan Arul , Kurokawa Ryo , Pratt Drew , Yadav Viveka N. , Grill Jacques , Kline Cassie , Mueller Sabine , Resnick Adam , Nazarian Javad , Allen Joshua E. , Odia Yazmin , Gardner Sharon L. , Koschmann Carl
Published: September 2024

GSEA analysis of genes with significantly lower H3K27ac at promoters and enhancers and reduced gene expression in DIPG007 cells treated with ONC201 versus vehicle.
Table S10 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways
Authors: Venneti Sriram , Kawakibi Abed Rahman , Ji Sunjong , Waszak Sebastian M. , Sweha Stefan R. , Mota Mateus , Pun Matthew , Deogharkar Akash , Chung Chan , Tarapore Rohinton S. , Ramage Samuel , Chi Andrew , Wen Patrick Y. , Arrillaga-Romany Isabel , Batchelor Tracy T. , Butowski Nicholas A. , Sumrall Ashley , Shonka Nicole , Harrison Rebecca A. , de Groot John , Mehta Minesh , Hall Matthew D. , Daghistani Doured , Cloughesy Timothy F. , Ellingson Benjamin M. , Beccaria Kevin , Varlet Pascale , Kim Michelle M. , Umemura Yoshie , Garton Hugh , Franson Andrea , Schwartz Jonathan , Jain Rajan , Kachman Maureen , Baum Heidi , Burant Charles F. , Mottl Sophie L. , Cartaxo Rodrigo T. , John Vishal , Messinger Dana , Qin Tingting , Peterson Erik , Sajjakulnukit Peter , Ravi Karthik , Waugh Alyssa , Walling Dustin , Ding Yujie , Xia Ziyun , Schwendeman Anna , Hawes Debra , Yang Fusheng , Judkins Alexander R. , Wahl Daniel , Lyssiotis Costas A. , de la Nava Daniel , Alonso Marta M. , Eze Augustine , Spitzer Jasper , Schmidt Susanne V. , Duchatel Ryan J. , Dun Matthew D. , Cain Jason E. , Jiang Li , Stopka Sylwia A. , Baquer Gerard , Regan Michael S. , Filbin Mariella G. , Agar Nathalie Y.R. , Zhao Lili , Kumar-Sinha Chandan , Mody Rajen , Chinnaiyan Arul , Kurokawa Ryo , Pratt Drew , Yadav Viveka N. , Grill Jacques , Kline Cassie , Mueller Sabine , Resnick Adam , Nazarian Javad , Allen Joshua E. , Odia Yazmin , Gardner Sharon L. , Koschmann Carl
Published: September 2024

Upregulated and downregulated metabolites in DIPG007 cells treated with ONC201 versus vehicle.
Supplementary Data S2 from Clinical efficacy of ONC201 in H3K27M-mutant diffuse midline gliomas is driven by disruption of integrated metabolic and epigenetic pathways
Authors: Venneti Sriram , Kawakibi Abed Rahman , Ji Sunjong , Waszak Sebastian M. , Sweha Stefan R. , Mota Mateus , Pun Matthew , Deogharkar Akash , Chung Chan , Tarapore Rohinton S. , Ramage Samuel , Chi Andrew , Wen Patrick Y. , Arrillaga-Romany Isabel , Batchelor Tracy T. , Butowski Nicholas A. , Sumrall Ashley , Shonka Nicole , Harrison Rebecca A. , de Groot John , Mehta Minesh , Hall Matthew D. , Daghistani Doured , Cloughesy Timothy F. , Ellingson Benjamin M. , Beccaria Kevin , Varlet Pascale , Kim Michelle M. , Umemura Yoshie , Garton Hugh , Franson Andrea , Schwartz Jonathan , Jain Rajan , Kachman Maureen , Baum Heidi , Burant Charles F. , Mottl Sophie L. , Cartaxo Rodrigo T. , John Vishal , Messinger Dana , Qin Tingting , Peterson Erik , Sajjakulnukit Peter , Ravi Karthik , Waugh Alyssa , Walling Dustin , Ding Yujie , Xia Ziyun , Schwendeman Anna , Hawes Debra , Yang Fusheng , Judkins Alexander R. , Wahl Daniel , Lyssiotis Costas A. , de la Nava Daniel , Alonso Marta M. , Eze Augustine , Spitzer Jasper , Schmidt Susanne V. , Duchatel Ryan J. , Dun Matthew D. , Cain Jason E. , Jiang Li , Stopka Sylwia A. , Baquer Gerard , Regan Michael S. , Filbin Mariella G. , Agar Nathalie Y.R. , Zhao Lili , Kumar-Sinha Chandan , Mody Rajen , Chinnaiyan Arul , Kurokawa Ryo , Pratt Drew , Yadav Viveka N. , Grill Jacques , Kline Cassie , Mueller Sabine , Resnick Adam , Nazarian Javad , Allen Joshua E. , Odia Yazmin , Gardner Sharon L. , Koschmann Carl
Published: September 2024

Protocol for NCT03134131, ONC201-018: Expanded Access to ONC201 for Patients with H3K27M-mutant and/or Midline High Grade Gliomas.
Fig. S9 from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression
Authors: Ye Jiayu , Baer John M. , Faget Douglas V. , Morikis Vasilios A. , Ren Qihao , Melam Anupama , Delgado Ana Paula , Luo Xianmin , Bagchi Satarupa Mullick , Belle Jad I. , Campos Edward , Friedman Michael , Veis Deborah J. , Knudsen Erik S. , Witkiewicz Agnieszka K. , Powers Scott , Longmore Gregory D. , DeNardo David G. , Stewart Sheila A.
Published: September 2024

Supplementary figure S9 shows quantification of NK cells in INK and ABT737 treated mice, gating strategy for NK cells, and IHC and associated quantification of NK cells in tissue.
Fig. S3 from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression
Authors: Ye Jiayu , Baer John M. , Faget Douglas V. , Morikis Vasilios A. , Ren Qihao , Melam Anupama , Delgado Ana Paula , Luo Xianmin , Bagchi Satarupa Mullick , Belle Jad I. , Campos Edward , Friedman Michael , Veis Deborah J. , Knudsen Erik S. , Witkiewicz Agnieszka K. , Powers Scott , Longmore Gregory D. , DeNardo David G. , Stewart Sheila A.
Published: September 2024

Supplementary figure S3 shows mIHC and shows vCAF and image analysis masking strategy.
Fig. S2 from Senescent CAFs Mediate Immunosuppression and Drive Breast Cancer Progression
Authors: Ye Jiayu , Baer John M. , Faget Douglas V. , Morikis Vasilios A. , Ren Qihao , Melam Anupama , Delgado Ana Paula , Luo Xianmin , Bagchi Satarupa Mullick , Belle Jad I. , Campos Edward , Friedman Michael , Veis Deborah J. , Knudsen Erik S. , Witkiewicz Agnieszka K. , Powers Scott , Longmore Gregory D. , DeNardo David G. , Stewart Sheila A.
Published: September 2024

Supplementary figure S2 shows scRNA-Seq from MMTV-PyMT mice focusing on CAFs and SA-BGal staining.
Data from Tracing founder mutations in circulating and tissue-resident follicular lymphoma precursors
Authors: Schroers-Martin Joseph G. , Soo Joanne , Brisou Gabriel , Scherer Florian , Kurtz David M. , Sworder Brian J. , Khodadoust Michael S. , Jin Michael C. , Bru Agnes , Liu Chih Long , Stehr Henning , Vineis Paolo , Natkunam Yasodha , Teras Lauren R. , Song Joo Y. , Nadel Bertrand , Diehn Maximilian , Roulland Sandrine , Alizadeh Ash A.
Published: September 2024

Abstract
Follicular lymphomas (FL) are characterized by BCL2 translocations, often detectable in blood years before FL diagnosis, but also observed in aging healthy individuals suggesting additional lesions are required for lymphomagenesis. We directly characterized early cooperating mutations by ultra-deep sequencing of pre-diagnostic blood and tissue specimens from 48 subjects who ultimately developed FL. Strikingly, CREBBP lysine acetyltransferase (KAT) domain mutations were the most commonly observed precursor lesions, and largely distinguished patients developing FL (14/48, 29%) from healthy adults with or without detected BCL2 rearrangements (0/13, p=0.03 and 0/20, p=0.007, respectively). CREBBP variants were detectable a median of 5.8 years before FL diagnosis, were clonally selected in FL tumors, and appeared restricted to the committed B-cell lineage. These results suggest that mutations affecting the CREBBP KAT domain are common lesions in FL cancer precursor cells (CPC), with potential for discriminating subjects at risk of developing FL or monitoring residual disease.
Data from Mitophagy promotes resistance to BH3 mimetics in acute myeloid leukemia
Authors: Glytsou Christina , Chen Xufeng , Zacharioudakis Emmanouil , Al-Santli Wafa , Zhou Hua , Nadorp Bettina , Lee Soobeom , Lasry Audrey , Sun Zhengxi , Papaioannou Dimitrios , Cammer Michael , Wang Kun , Zal Tomasz , Zal Malgorzata Anna. , Carter Bing Z. , Ishizawa Jo , Tibes Raoul , Tsirigos Aristotelis , Andreeff Michael , Gavathiotis Evripidis , Aifantis Iannis
Published: September 2024

Abstract
BH3-mimetics are used as an efficient strategy to induce cell death in several blood malignancies, including acute myeloid leukemia (AML). Venetoclax, a potent BCL-2 antagonist, is used clinically in combination with hypomethylating agents for the treatment of AML. Moreover, MCL-1 or dual BCL-2/BCL-xL antagonists are under investigation. Yet, resistance to single or combinatorial BH3-mimetics therapies eventually ensues. Integration of multiple genome-wide CRISPR/Cas9 screens revealed that loss of mitophagy modulators sensitizes AML cells to various BH3-mimetics targeting different BCL-2 family members. One such regulator is MFN2, whose protein levels positively correlate with drug resistance in patients with AML. MFN2 overexpression is sufficient to drive resistance to BH3-mimetics in AML. Insensitivity to BH3-mimetics is accompanied by enhanced mitochondria-endoplasmic reticulum interactions and augmented mitophagy flux which acts as a pro-survival mechanism to eliminate mitochondrial damage. Genetic or pharmacologic MFN2 targeting synergizes with BH3-mimetics by impairing mitochondrial clearance and enhancing apoptosis in AML.
Data from Dual immune checkpoint blockade induces analogous alterations in the dysfunctional CD8+ T cell and activated Treg compartment
Authors: van der Leun Anne M. , Traets Joleen J.H. , Vos Joris L. , Elbers Joris B.W. , Patiwael Sanne , Qiao Xiaohang , Machuca-Ostos Mercedes , Thommen Daniela S. , Haanen John B.A.G. , Schumacher Ton N.M. , Zuur Charlotte L.
Published: September 2024

Abstract
To dissect the effect of neoadjuvant PD-1 and CTLA4 blockade on intratumoral T cells in treatment-naive head and neck squamous cell carcinoma, we analyzed primary tumor immune infiltrates from responding and non-responding patients. At baseline, a higher ratio between active (4-1BB/OX-40+) and inactive regulatory CD4+ T cells was associated with immunotherapy response. Furthermore, upon therapy, this active Treg population showed a profound decrease in responding patients. In an analogous process, intratumoral dysfunctional CD8+ T cells displayed decreased expression of activity and dysfunction-related genes in responding patients, while in clinical non-responders NK cells showed an increased cytotoxic profile early upon treatment. These data reveal immunological changes in response to dual PD-1/CTLA4 blockade, including a parallel remodeling of presumed tumor-reactive Treg and CD8+ T cell compartments in responding patients, and indicate that the presence of activated Tregs at baseline may be associated with response.
Supplementary Figures S1-S5 from Microparticle-delivered Cxcl9 prolongs Braf inhibitor efficacy in melanoma
Authors: Romano Gabriele , Paradiso Francesca , Li Peng , Shukla Pooja , Barger Lindsay N. , El Naggar Olivia , Miller John P. , Liang Roger J. , Helms Timothy L. , Lazar Alexander J. , Wargo Jennifer A. , Taraballi Francesca , Costello James C. , Kwong Lawrence N.
Published: September 2024

Supplementary Figures S1-S5
Supplementary Data from HDAC3 inhibition promotes anti-tumor immunity by enhancing CXCL10 mediated chemotaxis and recruiting of immune cells
Authors: Li Lili , Hao Shumin , Gao Meiling , Liu Junxiao , Xu Xin , Huang Jianfei , Cheng Genhong , Yang Heng
Published: September 2024

Supplementary Fig.S1-S9
Table S1-S2
Supplementary Movie from Discovery of podofilox as a potent cGAMP–STING signaling enhancer with antitumor activity
Authors: Zhang Conggang , Han Jing , Hu Shuiqing , Hu Yawei , Xu Yifang , Hou Yanfei , Yang Yinlong , Su Huili , Zhang Zhengyin , Liu Peng , Sun Xuxu
Published: September 2024

Movie
Supplementary legends from The immunopeptidome from a genomic perspective: Establishing the non-canonical landscape of MHC class I–associated peptides
Authors: Bedran Georges , Gasser Hans-Christof , Weke Kenneth , Wang Tongjie , Bedran Dominika , Laird Alexander , Battail Christophe , Zanzotto Fabio Massimo , Pesquita Catia , Axelson Håkan , Rajan Ajitha , Harrison David J. , Palkowski Aleksander , Pawlik Maciej , Parys Maciej , O'Neill J Robert. , Brennan Paul M. , Symeonides Stefan N. , Goodlett David R. , Litchfield Kevin , Fahraeus Robin , Hupp Ted R. , Kote Sachin , Alfaro Javier A.
Published: September 2024

Legends for Supplementary tables, supplementary figures, and supplementary notes.
Supplementary Data from EBV-upregulated B7-H3 inhibits NK cell–mediated antitumor function and contributes to nasopharyngeal carcinoma progression
Authors: Chen Haiwen , Duan Xiaobing , Deng Xiaohong , Huang Yingping , Zhou Xiang , Zhang Shanshan , Zhang Xiao , Liu Pingjuan , Yang Chaopin , Liu Guojun , Ren Qinqin , Xiong Yan , Zhu Bo , Zhang Jiexia , Xiang Tong
Published: September 2024

Supplementary Figures and Tables
Supplementary Methods File S1 from iBRIDGE: A Data Integration Method to Identify Inflamed Tumors from Single-Cell RNAseq Data and Differentiate Cell Type–Specific Markers of Immune-Cell Infiltration
Authors: Turan Tolga , Kongpachith Sarah , Halliwill Kyle , McLaughlin Robert T. , Binnewies Mikhail , Reddy Dhemath , Zhao Xi , Mathew Rebecca , Ye Shiming , Jacob Howard J. , Samayoa Josue
Published: September 2024

Turan et. al Supplementary Methods File S1
Supplementary Figures from iBRIDGE: A Data Integration Method to Identify Inflamed Tumors from Single-Cell RNAseq Data and Differentiate Cell Type–Specific Markers of Immune-Cell Infiltration
Authors: Turan Tolga , Kongpachith Sarah , Halliwill Kyle , McLaughlin Robert T. , Binnewies Mikhail , Reddy Dhemath , Zhao Xi , Mathew Rebecca , Ye Shiming , Jacob Howard J. , Samayoa Josue
Published: September 2024

Supplementary Figures S1-S6
Supplementary Figure 4 from MYC induces immunotherapy and interferon-γ resistance through downregulation of JAK2
Authors: Markovits Ettai , Harush Ortal , Baruch Erez N. , Shulman Eldad D. , Debby Assaf , Itzhaki Orit , Anafi Liat , Danilevsky Artem , Shomron Noam , Ben-Betzalel Guy , Asher Nethanel , Shapira-Frommer Ronnie , Schachter Jacob , Barshack Iris , Geiger Tamar , Elkon Ran , Besser Michal J. , Markel Gal
Published: September 2024

Supplementary Figure 4
Supplementary Fig. 9 from KRT17 promotes T-lymphocyte infiltration through the YTHDF2-CXCL10 axis in colorectal cancer
Authors: Liang Wenfeng , Liu Huashan , Zeng Ziwei , Liang Zhenxing , Xie Hao , Li Wenxin , Xiong Li , Liu Zhihang , Chen Mian , Jie Haiqing , Zheng Xiaobin , Huang Liang , Kang Liang
Published: September 2024

CXCL10 is indispensable for KRT7-mediated improved responsiveness to ICIs.
Supplementary Fig. 3-4 from KRT17 promotes T-lymphocyte infiltration through the YTHDF2-CXCL10 axis in colorectal cancer
Authors: Liang Wenfeng , Liu Huashan , Zeng Ziwei , Liang Zhenxing , Xie Hao , Li Wenxin , Xiong Li , Liu Zhihang , Chen Mian , Jie Haiqing , Zheng Xiaobin , Huang Liang , Kang Liang
Published: September 2024

KRT17 expression is positively correlated with CD3+ and CD8+ densities in tumor parenchyma and invasive margin in CRC.
Supplementary Fig. 2 from KRT17 promotes T-lymphocyte infiltration through the YTHDF2-CXCL10 axis in colorectal cancer
Authors: Liang Wenfeng , Liu Huashan , Zeng Ziwei , Liang Zhenxing , Xie Hao , Li Wenxin , Xiong Li , Liu Zhihang , Chen Mian , Jie Haiqing , Zheng Xiaobin , Huang Liang , Kang Liang
Published: September 2024

KRT17 has no effect on proliferation, migration and invasion of CRC cells.
Supplementary Figures from Single-Cell Profiling of CD8+ T Cells in Acute Myeloid Leukemia Reveals a Continuous Spectrum of Differentiation and Clonal Hyperexpansion
Authors: Desai Poonam N. , Wang Bofei , Fonseca Andre , Borges Pamella , Jelloul Fatima Zahra. , Reville Patrick K. , Lee Eric , Ly Christopher , Basi Akshay , Root Jessica , Baran Natalia , Post Sean M. , Deng Qing , Sun Hanxiao , Harmanci Arif O. , Burks Jared K. , Gomez Javier A. , DiNardo Courtney D. , Daver Naval G. , Alatrash Gheath , Konopleva Marina , Green Michael R. , Antunes Dinler A. , Futreal Andrew , Hao Dapeng , Abbas Hussein A.
Published: September 2024

All Supplementary Figures
Supplementary Figure 12 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer
Authors: Tsimberidou Apostolia M. , Guenther Kerstin , Andersson Borje S. , Mendrzyk Regina , Alpert Amir , Wagner Claudia , Nowak Anna , Aslan Katrin , Satelli Arun , Richter Fabian , Kuttruff-Coqui Sabrina , Schoor Oliver , Fritsche Jens , Coughlin Zoe , Mohamed Ali S. , Sieger Kerry , Norris Becky , Ort Rita , Beck Jennifer , Vo Henry Hiep. , Hoffgaard Franziska , Ruh Manuel , Backert Linus , Wistuba Ignacio I. , Fuhrmann David , Ibrahim Nuhad K. , Morris Van Karlyle. , Kee Bryan K. , Halperin Daniel M. , Nogueras-González Graciela M. , Kebriaei Partow , Shpall Elizabeth J. , Vining David , Hwu Patrick , Singh-Jasuja Harpreet , Reinhardt Carsten , Britten Cedrik M. , Hilf Norbert , Weinschenk Toni , Maurer Dominik , Walter Steffen
Published: September 2024

Supplementary Figure 12
Supplemental Figure 8 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer
Authors: Tsimberidou Apostolia M. , Guenther Kerstin , Andersson Borje S. , Mendrzyk Regina , Alpert Amir , Wagner Claudia , Nowak Anna , Aslan Katrin , Satelli Arun , Richter Fabian , Kuttruff-Coqui Sabrina , Schoor Oliver , Fritsche Jens , Coughlin Zoe , Mohamed Ali S. , Sieger Kerry , Norris Becky , Ort Rita , Beck Jennifer , Vo Henry Hiep. , Hoffgaard Franziska , Ruh Manuel , Backert Linus , Wistuba Ignacio I. , Fuhrmann David , Ibrahim Nuhad K. , Morris Van Karlyle. , Kee Bryan K. , Halperin Daniel M. , Nogueras-González Graciela M. , Kebriaei Partow , Shpall Elizabeth J. , Vining David , Hwu Patrick , Singh-Jasuja Harpreet , Reinhardt Carsten , Britten Cedrik M. , Hilf Norbert , Weinschenk Toni , Maurer Dominik , Walter Steffen
Published: September 2024

Supplemental Figure 8
Supplemental Figure 3 from Feasibility and Safety of Personalized, Multi-Target, Adoptive Cell Therapy (IMA101): First-In-Human Clinical Trial in Patients with Advanced Metastatic Cancer
Authors: Tsimberidou Apostolia M. , Guenther Kerstin , Andersson Borje S. , Mendrzyk Regina , Alpert Amir , Wagner Claudia , Nowak Anna , Aslan Katrin , Satelli Arun , Richter Fabian , Kuttruff-Coqui Sabrina , Schoor Oliver , Fritsche Jens , Coughlin Zoe , Mohamed Ali S. , Sieger Kerry , Norris Becky , Ort Rita , Beck Jennifer , Vo Henry Hiep. , Hoffgaard Franziska , Ruh Manuel , Backert Linus , Wistuba Ignacio I. , Fuhrmann David , Ibrahim Nuhad K. , Morris Van Karlyle. , Kee Bryan K. , Halperin Daniel M. , Nogueras-González Graciela M. , Kebriaei Partow , Shpall Elizabeth J. , Vining David , Hwu Patrick , Singh-Jasuja Harpreet , Reinhardt Carsten , Britten Cedrik M. , Hilf Norbert , Weinschenk Toni , Maurer Dominik , Walter Steffen
Published: September 2024

Supplemental Figure 3
Supplementary Data from T cell–mediated development of stromal fibroblasts with an immune-enhancing chemokine profile
Authors: Yan Ran , Moresco Philip , Gegenhuber Bruno , Fearon Douglas T.
Published: September 2024

Figure S1, S2, S3
Supplementary Table 1 from Systemic Alterations in Type-2 Conventional Dendritic Cells Leads to Impaired Tumor Immunity in Pancreatic Cancer
Authors: James C. Alston. , Baer John M. , Zuo Chong , Panni Usman Y. , Knolhoff Brett L. , Hogg Graham D. , Kingston Natalie L. , Kang Liang-I , Lander Varintra E. , Luo Jingqin , Tao Yu , Watson Mark A. , Aft Rebecca , Fields Ryan C. , Hawkins William G. , DeNardo David G.
Published: September 2024

Supplementary Table 1
Supplementary Figures from Small gene networks delineate immune cell states and characterize immunotherapy response in melanoma
Authors: Egan Donagh , Kreileder Martina , Nabhan Myriam , Iglesias-Martinez Luis F. , Dovedi Simon J. , Valge-Archer Viia , Grover Amit , Wilkinson Robert W. , Slidel Timothy , Bendtsen Claus , Barrett Ian P. , Brennan Donal J. , Kolch Walter , Zhernovkov Vadim
Published: September 2024

Supplementary Figures S1 and S2
Supplementary Table S8 from Immunogenetic metabolomics reveals key enzymes that modulate CAR T-cell metabolism and function
Authors: Renauer Paul , Park Jonathan J. , Bai Meizhu , Acosta Arianny , Lee Won-Ho , Lin Guang Han , Zhang Yueqi , Dai Xiaoyun , Wang Guangchuan , Errami Youssef , Wu Terence , Clark Paul , Ye Lupeng , Yang Quanjun , Chen Sidi
Published: September 2024

Supplementary Table S8